基本信息
浏览量:5
职业迁徙
个人简介
Personal Statement:
Our research is dedicated to the discovery of more effective therapies for the treatment of cancer, primarily breast cancer. There are several aspects to our work including drug discovery and target identification for subtypes of triple negative breast cancer and pediatric solid tumors, identification of the molecular mechanisms of the non-mitotic effects of diverse microtubule targeting drugs including their effects on oncogenic signaling pathways.
We conduct a mechanism-blind screening program to identify new anticancer leads from natural product prefractionated extracts from plants, marine organisms and fungi available from the Natural Products Branch of National Cancer Institute and from other collaborators. Leads discovered though our primary screening efforts are subject to bioassay-guided fractionation in collaboration with the Cichewicz laboratory, Institute for Natural Product Applications and Research Technologies at The University of Oklahoma. Isolated compounds are evaluated for their molecular mechanisms of action and in vivo antitumor potential. When the need arises we optimize natural product lead compounds with medicinal chemistry optimization in collaboration with Dr. Stan McHardy, Director of Medicinal Chemistry at the Center for Innovative Drug Discovery at the University of Texas at San Antonio.
Our research is dedicated to the discovery of more effective therapies for the treatment of cancer, primarily breast cancer. There are several aspects to our work including drug discovery and target identification for subtypes of triple negative breast cancer and pediatric solid tumors, identification of the molecular mechanisms of the non-mitotic effects of diverse microtubule targeting drugs including their effects on oncogenic signaling pathways.
We conduct a mechanism-blind screening program to identify new anticancer leads from natural product prefractionated extracts from plants, marine organisms and fungi available from the Natural Products Branch of National Cancer Institute and from other collaborators. Leads discovered though our primary screening efforts are subject to bioassay-guided fractionation in collaboration with the Cichewicz laboratory, Institute for Natural Product Applications and Research Technologies at The University of Oklahoma. Isolated compounds are evaluated for their molecular mechanisms of action and in vivo antitumor potential. When the need arises we optimize natural product lead compounds with medicinal chemistry optimization in collaboration with Dr. Stan McHardy, Director of Medicinal Chemistry at the Center for Innovative Drug Discovery at the University of Texas at San Antonio.
研究兴趣
论文共 228 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Leila Takahashi‐Ruiz,Charles S. Fermaintt, Nancy Wilkinson, P. S. H. Chan,Susan L. Mooberry,April L. Risinger
Cancer Researchno. 7_Supplement (2023): 6397-6397
April L. Risinger, Evelyn M. Jackson,Lisa A. Polin, Gregory L. Helms, Desiree A. LeBoeuf, Patrick A. Joe,Elizabeth Hopper-Borge, Richard F. Ludueña, Gary D. Kruh,Susan L. Mooberry
crossref(2023)
April L. Risinger, Evelyn M. Jackson, Lisa A. Polin, Gregory L. Helms, Desiree A. LeBoeuf, Patrick A. Joe,Elizabeth Hopper-Borge,Richard F. Ludueña, Gary D. Kruh,Susan L. Mooberry
crossref(2023)
April L. Risinger, Evelyn M. Jackson,Lisa A. Polin, Gregory L. Helms, Desiree A. LeBoeuf, Patrick A. Joe,Elizabeth Hopper-Borge, Richard F. Ludueña, Gary D. Kruh,Susan L. Mooberry
crossref(2023)
Bioorganic & Medicinal Chemistry (2023): 117217-117217
April L. Risinger, Evelyn M. Jackson,Lisa A. Polin, Gregory L. Helms, Desiree A. LeBoeuf, Patrick A. Joe,Elizabeth Hopper-Borge, Richard F. Ludueña, Gary D. Kruh,Susan L. Mooberry
crossref(2023)
April L. Risinger, Evelyn M. Jackson,Lisa A. Polin, Gregory L. Helms, Desiree A. LeBoeuf, Patrick A. Joe,Elizabeth Hopper-Borge, Richard F. Ludueña, Gary D. Kruh,Susan L. Mooberry
crossref(2023)
Leila Takahashi‐Ruiz,Charles S. Fermaintt, Nancy Wilkinson, P. S. H. Chan,Susan L. Mooberry,April L. Risinger
Journal of clinical and translational scienceno. s1 (2023): 128-128
引用0浏览0引用
0
0
April L. Risinger, Evelyn M. Jackson,Lisa A. Polin, Gregory L. Helms, Desiree A. LeBoeuf, Patrick A. Joe,Elizabeth Hopper-Borge, Richard F. Ludueña, Gary D. Kruh,Susan L. Mooberry
crossref(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn